株式会社 東京プレスＴ
|
|
|
- ときな じゅふく
- 5 years ago
- Views:
Transcription
1 ALL Philadelphia ALL MLL ALL ALL ALL ALL Philadelphia MLL acute lymphoblastic leukemia, ALL Philadelphia Ph+ ALL MLL mixed lineage leukemia MLL+ ALL ALL chronic myeloid leukemia, CML imatinib ALL ALL 1 Ph t 9;22 q34;q11 22q11 bcr
2 60 breakpoint cluster region 9q34 c-abl bcr intron 1 minor bcr, m-bcr intron 2 3 major bcr, M-bcr c-abl head to tail m-bcr exon 1 B1 c-abl exon 2 a2 B1-a2 mrna p190 BCR-ABL M-bcr bcr exon 2 b2 exon 3 b3 a2 b2-a2 mrna b3-a2 mrna p210 BCR-ABL CML p210 BCR-ABL Ph+ALL p190 BCR-ABL Ph B1-a2 mrna, b2-a2 mrna, b3-a2 mrna reverse transcription (RT)-polymerase chain reaction PCR 1 Ph+ALL a2 b2-a3 b3-a3 mrna p203 BCR-ABL 1 RT-PCR bcr-abl mrna bcr-abl fluorescence-in situ hybridization FISH bcr ABL BCR-ABL ABL p145 MLL 11q23 MLL+ 30 MLL+ALL t 4;11 q21;q23 t 11;19 q23;p13 t 9;11 p21;q23 AF4, ENL, AF9 in-frame 11;19 MLL+ALL RT-PCR mrna MLL-AF4, MLL-ENL, MLL-AF9 MLL+ALL MLL MLL split signal FISH 2 Ph+ALL BCR-ABL 4 BCR- ABL BCR-ABL Ph+ leukemogenesis 2 BCR-ABL BCR- ABL CML MLL+ leukemogenesis 2 3,4 MLL 2 MLL homeobox Hoxa9 MLL histone methyltransferase cofactor complex Men1 multiple endocrine neoplasia type 1
3 61 menin Hox Men1 MLL-AF9 Hoxa9 transform menin Hox MLL+ALL leukemogenesis 5,6 MLL+ALL MEIS mouse ecotropic virus integration site 1 Hoxa9 FLT3 MLL in vitro MLL knock-in 7 Cre-lox translocation 8 MLL+ Ono R 9 MLL-SEPT6 MLL-ENL MLL-SEPT6 MLL- ENL FLT3 internal tandem duplication lineage MLL+ MLL 3 ALL Ph+ ALL ALL 1-5 MLL+ALL ALL 80 3 ALL MLL+ALL ALL acute myeloid leukemia, AML Ph+ALL MLL+ALL ALL ALL complete remission, CR 90 Ph+ALL 5 event free survival, EFS MLL+ALL 3 4 EFS ,12 1CR hematopoietic stem cell transplantation, SCT Ph+ALL 13 MLL+ALL SCT 4 ALL B CD19 CD79a CD13, CD33 Ph+ALL B-precursor ALL common ALL antigen CALLA, CD10 MLL+ALL CD10 KOR-SA3544 Ph+ALL Ph+ALL 14 CEA carcinoembrionic antigen, CD66e superfamily nonspecific cross-reacting antigen NCA 50/90 CD66c 15
4 62 5 p53 Rb ALL cyclin-dependent kinase CDK 4 CDK6 inhibitor CDKI p16/ink4a Ph+ALL T ALL MLL+ALL p16 p16 p16 5-aza-2 deoxycitidine p16 16 p16 9p21 p16 7 ALL p16 17 p16 ALL Ph+ MLL+ALL p16 1 ALL key drugs prednisolone, L-asparaginase, vincristine Hongo T 20 3 ALL 11 Ph+ MLL+ALL in vitro 40 Ph+ALL 21 ALL ALL poor responder good responder ALL 1-5 /cell /cell heat shock protein-90 HSP-90 HSP-90 Ph+ MLL+ 1 HSP-90 HSP G-CSF G-CSF G-CSFR G-CSF G-CSF MLL+ALL MLL+ALL G-CSFR G-CSFR G-CSF 23 Ph+ALL G-CSFR G-CSF
5 63 MLL+ALL ALL Ph+AML G-CSF G-CSF Ph+AML G-CSF autocrine mechanism 24 MLL+ Ph+ALL G-CSF SCT G-CSF G-CSF 2 thrombopoietin TPO TPO c-mpl c-mpl G-CSFR MLL+ Ph+ALL c-mpl c-mpl TPO 25 3 Fms-like tyrosine kinase 3 FLT3 FLT3 3 MLL+ALL FLT3 B-precursor ALL FLT3 ligand FL Ph+ALL 1;19 ALL MLL+ALL G1 arrestcdki p27/kip1 MLL+ALL STAT signal transducer and activator of transcription 5 FL MLL+ALL quiescence FL FL 26 AML VLA-4 AML minimal residual disease, MRD 27 FL MLL+ALL MRD MLL+ALL BCR-ABL BCR- ABL Ph+ leukemogenesis BCR-ABL imatinib STI571 Ph+ CML CML Ph+ALL Ph+ALL phase 1 study mg 600 mg
6 64 1 MLL+ALL MRD FL/FLT3 interaction FL MLL+ALL FL/FLT3 interaction MRD FLT3 MLL+ALL FL/FLT3 interaction MLL+ALL 260 mg/m mg/m 2 28 Ph+ALL n = 92 imatinib mg/day 29 CR 95 PCR BCR-ABL CR SCT Ph+ALL imatinib front-line therapy imatinib imatinib imatinib ABL ATP ATP BCR-ABL ATP imatinib imatinib Glu255 Thr315 CML Ph+ALL minor clone imatinib minor clone 30 imatinib Ph+ ATP ONO12380 imatinib ATP affinity nilotinib AMN107 dasatinib Lyn NS-187 CNS T315I AG490 tryphostin WP1130 Aurora MK JAK2 Janus kinase 2 JAK2
7 65 STATs interferon-γ erythropoietin TPO IL-3 GM-CSF AG490 tryphostin B-precursor ALL JAK2 35 B-precursor ALL JAK2 Ph+ALL MLL+ALL Ph+ALL MLL+ALL SCT ex vivo purging 36 3 peroxisome proliferator-activated receptor PPAR PPAR PPARα, PPARβ, PPARγ PPARγ Troglitazone TGZ PPARγ 37 TGZ Tcf-4 c-myc 38 TGZ PPARα PPARγ TZD18 Ph+ALL 39 4 FLT3 NGF TrkA CEP-701 Cephalon PKC PKC412 Novartis VEGF SU11248 Sugen FLT3 FLT3 ITD AML MLL+ALL FLT3 FLT3 D MLL+ D835 wild-type FLT3 STAT5, MAPK, Akt 40 FLT3 PKC FLT3 MLL+ALL FLT3/FL interaction MLL+ALL CEP histon deacetylase HDAC leukemogenesis histon acetyltransferase HAT histon deacetylase HDAC HDAC HDACI AML MDS ALL
8 66 HDACI trichostatin A TSA ALL Ph+ MLL+ALL 42 HSP-90 HDAC6 class IIb HDAC HDACI HSP-90 HSP-90 client proteins BCR-ABL FLT3 proteasome 43 ALL 4 Fas ligand FasL TNF-related apoptosisinducing ligand TRAIL TNF Fas DR4/DR5 FasL TRAIL T CTL NK SCT graftversus-leukemia, GVL kill FasL TRAIL 2 Ph+ALL Fas recombinant soluble FasL agonistic DR4/DR5 recombinant soluble TRAIL 44 MLL+ALL FasL DR4/DR5 TRAIL 45 3 Ph+ALL TRAIL 2 T CTL NK CTL NK FasL and/or TRAIL Fas and/or DR4/DR5 CTL NK 3 B-precursor TRAIL MLL+ALL FLT3-D835 TRAIL MLL+ALL SCT GVL MLL+ALL FasL TRAIL SCT GVL
9 67 NK NK MHC SCT NK NK perforin NK NK KIRs killer-cell immunoglobulin-like receptors CD158b KIR2DL2/3 group 1 HLA-C Cw1,Cw3 CD158a KIR2DL1 group 2 HLA- C Cw2,Cw4 ligand 46 HLA-C group 1 90 group 2 10 group 1 group 1/group 2 NK CD158a NK NK GVL AML HLA SCT MLL+ALL NK HLA-C SCT 1 47 NK MLL+ALL MLL+ALL NK MLL+ALL HLA-C group 1 HLA-C group 1/group 2 NK MLL+ALL NK GVL ALL 20 1 Inukai T, Sugita K, Suzuki T, et al: A novel 203 kd aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphobastic leukaemia. Brit J Haematol 85: , Wong S, Witte ON: Modeling Philadelphia chromosome positive leukemias. Oncogene 20: , Ayton PM, Cleary ML: Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20: , Daser A, Rabbitts TH: Extending the repertorie of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18: , Yokoyama A, Somervaille TC, Smith KS, et al: The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123: , Chen YX, yan J, Keeshan K, et al: The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci USA 103: , Corral J, Lavenir I, Immpey H, et al: An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion genes. Cell 85: , Forster A, Panel R, Drynan LF, et al: Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 3: , Ono R, Nakajima H, Ozaki K, et al: Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 115: , Arico M, Valsecchi G, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342: , 2000.
10 68 11 Chessles JM, Harrison CJ, Watson SL, et al: Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols Br J Haematol 117: , Isoyama K, Eguchi M, Hibi S, et al: Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Br J Haematol 118: , Mori T, Manabe A, Tsuchida M, et al: Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosomepositive acute lymphoblastic leukemia; Tokyo children s Cancer Study Group (TCCSG) studies L89-12 and L Med Pediatr Oncol 37: , Mori T, Sugita K, Suzuki T, et al: A novel monoclonal antibody, KOR-SA3544, which reacts to Philadelphia chromosome-positive acute lymphoblastic cells with high sensitivity. Leukemia 9: , Sugita K, Mori T, Yokota S, et al: The KOR- SA3544 antigen predominantly expressed on surface of Philadelphia chromosome-positive acute lymphoblastic cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells. Leukemia 13: , Nakamura M, Sugita K, Inukai T, et al: p16/mts1/ink4a gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 13: , Nakamura M, Sugita K, Inukai T, et al: Abnormalities of the p16 INK4A gene in childhood B-precursor acute lymphoblastic leukemia without nonrandom translocations: analysis of seven matched pairs of primary leukemia and corresponding cell lines. Leukemia 15: , Armstrong SA, Staunton JE, Silverman JB, et al: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet 30: 41 47, Tsutsumi S, Taketani T, Nishimura K, et al: Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 63: , Hongo T, Yamada S, Yajima S, et al: Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. Int J Hematol 70: , Hongo T, Okada S, Inoue N, et al: Two groups of Philadelphia chromosome-positive childhood acute leukemia classified by pretreatment multidrug sensitivity or resistance in vitro testing. Int J Hematol 76: , Kojika S, Sugita K, Inukai Y, et al: Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kda heat shock proteins. Leukemia 10: , Inukai T, Sugita K, Iijima K, et al: Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. Leukemia 12: , Inukai T, Sugita K, Mitsui K, et al: Participation of granulocyte colony-stimulating factor in the growth regulation of leukemia cells from Philadelphia chromosome-positive acute leukemia and blast crisis of chronic myeloid leukemia. Leukemia 14: , Iijima K, Sugita K, Inukai T, et al: Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome. Leukemia 14: , Furuichi Y, Goi K, Inukai T, et al: Fms-like kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. Cancer Res 67: , Matsunaga T, Takemoto N, Sato T, et al: Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myeologenous leukemia. Nature Med 9: , Champagne MA, Capdeville R, Krailo M, et al: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children s Oncology Group phase 1 study. Blood 104: , Wassmann B, Pfeifer H, Goekbuget N, et al: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 108: , Hofmann W, Komor M, Wassmann B, et al: presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102: , 2003.
11 69 31 Gumireddy K, Baker SJ, Cosenza SC, et al: A non- ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc natl Acad Sci USA 102: , Weiberg E, Manley PW, Breitenstein W, et al: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: , Talpaz m, Shah NP, Kantarjian H, et al: Dosatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 354: , Kimura S, Naito H, Segawa H, et al: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106: , Meydan N, Grunberger T, Dadi H, et al: Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 379: , Miyamoto N, Sugita K, Goi K, et al: The JAK2 inhibitor AG490 predominantly abrogate the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 15: , Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med 4: , Yamakawa-Karakida, Sugita K, Inukai T, et al: Ligand activation of peroxisome proliferator-activated receptor induces apoptosis of leukemia cells by downregulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ 9: , Lui H, Zang C, Fenner MH, et al: Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 107; , Taketani T, Taki T, Sugita K, et al: FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103: , Takahashi K, Goi K, Furuichi Y, et al: PKC412, a FLT3 inhibitor, effectively induces apoptosis of leukemia cells with 11q23 translocation particularly with D835 mutation. Blood 104: 522a, Sato H, Goi K, Sugita K, et al: The histon-deacetylase inhibitor Trichostatin A effectively induces p21-mediated cell cycle arrest and caspase-dependent apoptosis in B-precursor leukemia cells. Blood 102: 1382a, Rao R, Fiskus W, Herger B, et al: Inhibition of histon deacetylase (HDAC6) 6 and/or heat shock protein (HSP) 90: a strategy to abrogate multi-level protective responses to misfolded proteins induced by proteasome inhibitors in human leukemia cells. Blood 108: 80a, Uno K, Inukai T, Kayagaki N, et al: TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosomepositive leukemia cells. Blood 101: , Inukai T, Zhang X, Goto M, et al: Resistance of infant leukemia with MLL rearrangement to TNF-related apoptosis-inducing ligand: possible mechanism for poor sensitivity to anti-leukemic immunity. Leukemia 20: , Farag S, VanDeusen JB, Fehniger TA, et al: Biology and clinical impact of human natural killer cells. Int J Hematol 78: 7 17, Triplett B, Handgretinger R, Pui CP, et al: KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood, 107: , 2006.
2 犬 飼 図 1. 小児急性リンパ性白血病の生存率が 90 に 達したことを伝える 2006 年の St Jude 小児 病院のホーム ページ 図 2. 山梨大学小児科における小児急性リンパ性白 血病症例数の推移 棒グラフは年間の症例数を 折れ線グラフは 累積症例数を示す 岳 史 図 3. 各年代
27 1 1 11 20131 1985 2010 96 1990 9 33.3 15.7 1991 2000 45 80.0 6.0 2001 2010 42 87.0 5.5 I 30 409-3898 1110 2012 9 4 2012 10 5 1 1970 1980 St Jude 90 1 2006 1985 2011 100 2 1992 3 St Jude 2 犬 飼 図 1. 小児急性リンパ性白血病の生存率が
サイトメトリー12-1.indd
Cell Growth Inhibition and Apoptosis in Cancer Cells Kazuki Omoteyama, Shoichi Inoue and Alaa-eldin Salah-eldin Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth
untitled
Shinichiro Okamoto MD, PhD Keio University School of Medicine Tokyo Japan vincristine) Berberidaceae etoposide VP-16) MRD 10 12 PCR 10 10 10 8 10 6 10 4 10 2 ( CR) ( CR) AML Study n Ind Consol % 3
研究成果報告書
21 5 28 2007 2008 CARElk CARPXR CAR CAR EST cdna CAR CAR 10FCS 96 SW480 HepG2 anti-lamin A/C anti-phospho-histone H3 anti-cyclin D1 G1 anti-cyclin A S CAR lamin A/C CAR Fig. 1 Lamin A/C /G1 lamin A/C G1
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
PowerPoint Presentation
1 Cutaneous T- cell lymphoma) 2) 2001 WHO - - - PS LDH soluble IL- B 38.5 C 10 International Prognostic Index IPI International prognostic factor and index Prognostic factor >60 LDH > PS 2-4 Stage III
2
2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary
16 MHC 2018; 25 (1) 参加費 1 2, , ,000 会議等 :00 13: :00 13: :20 会場地図 TEL JR 350 m 57
Major Histocompatibility Complex 2018; 25 (1): 56 82 抄録集 16 2018 3 3 7 2 4 43 TEL 06 6962 7001 594 1101 840 TEL 0725 56 1220 56 16 MHC 2018; 25 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 3 13:00 13:10 2 3
ミニレビュー
Molecular mechanisms of the suppression of inflammation by thermal stress Ryosuke Takii Department of Biochemistry and Molecular Biology, Yamaguchi University Graduate School of Medicine, Ube 755-8505,
サイトメトリー20-2.indd
Nobutaka Kiyokawa M.D., Ph.D. 1, 2), Keiko Onda M.D., Ph.D. 1, 2, 3), Kunihiko Takano C.C. 4), Junichiro Fujimoto M.D., Ph.D. 1, 2), Atsushi Manabe M.D., Ph.D. 2, 5), Katsuyoshi Ko M.D., Ph.D. 2, 6), Akira
MHC 2013; 20 (1) 11 参加費 1 2, , ,000 会議等 :50 14: :30 13: :00 会場地図 参天製薬株式会社本社案内図 TEL 新大阪駅より
Major Histocompatibility Complex 2013; 20 (1): 63 89 抄録集 11 2013 2 2 3 9 19 TEL: 06 6321 7000 630 0293 1248 1 TEL: 0743 77 0880 E-mail: tubaki@nara.med.kindai.ac.jp 63 MHC 2013; 20 (1) 11 参加費 1 2,000 2
03慢性骨髄性白血病CML.indd
慢* 59 病CML略語一覧 Ⅰ クリニカルクエスチョン一覧 Ⅱ 略語一覧 慢性骨髄性白血病 CML CQ 1 小児 CML の標準的治療は何か CQ 2 小児 CML 治療における造血幹細胞移植の役割は何か CML (Chronic Myelocytic Leukemia, 慢性骨髄性白血病 ) TKI (Tyrosine Kinase Inhibitor, チロシンキナーゼ阻害薬 ) CHR (Complete
好中球とPTX3
Neutrophils and pentraxin 3 Makoto Naito, Alexander S. Savchenko and Akira Inoue Pentraxin 3 (PTX3) is the first identified long pentraxin, and is rapidly produced and released by several cell types in
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
Detection methods of minimal residual disease and their prognostic value in patients with malignant hematological diseases はじめに (m
92 124 3 92 96 2015 Detection methods of minimal residual disease and their prognostic value in patients with malignant hematological diseases はじめに (minimal residual disease: MRD) MRD MRD ( 1) MRD PCR
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
肺癌第50巻第4号
1 Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan; 2 Department of Thoracic Surgery, Aichi Cancer Center, Japan;
Microsoft Word - ＴＩＰ２００6-3-TGN doc
TIP 2006 3 Vol 21 No3 p21-24 TGN1412 I NPO 3 13 15 [1,2] I TGN1412 18 40 1 ICU 19 6 4 3 [3] The Medicines and Healthcare Products Regulatory Agency MHRA [2] TGN1412 TGN1412 CD28-SuperMAB T TGN1412 T superagonistic
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
untitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
5698-5701. 5) Kadowaki T, Tobe K, Honda-Yamamoto R, Tamemoto H, Kaburagi Y, Momomura K, et al.: Signal transduction mechanism of insulin and insulin-like growth factor-1. Endocrine J 1996; 43: 33-41. 6)
北陸地域アイソトープ研究会誌第７号
IMRT Hyper-radiosensitivity and Increased radioresistance Radiation adaptive response Radiation-induced bystander effect 0.5 Gy hyper-radiosennsitivity HRS 0.5 Gy increased radioresistance IRR HRS IRR
1. Ishida-Yamamoto A, Dera i son C, Bonnart C, B i toun E, Robinson R, O'Brien TJ,Wakamatsu K, Ohtsubo S, Takahashi H, Hashimoto Y, Dopping-Hepenstal PJ, McGrath JA, lizuka H, Richard G, Hovnanian A. LEKTI
計算機生命科学の基礎II_
Ⅱ 1.4 atsushi_doi@cell-innovator.com 812-8582 3-1-1 8 806 http://www.cell-innovator.com BioGPS Connectivity Map The Cancer Genome Atlas (TCGA); cbioportal GO DAVID, GSEA WCGNA BioGPS http://biogps.org/
Major Histocompatibility Complex 2018; 25 (2): 抄録集 2 HLA A 3 128
Major Histocompatibility Complex 2018; 25 (: 128 138 抄録集 2018 4 14 A 3 128 MHC 2018; 25 ( HLA 2013 10.5 10 8 12 10 8 2016 CD34 + HLA NC 10 8 CD34 + CD34 + 10 6 NC10.5 2013.Apr 2014.Mar NC11 2014.Apr 2016.Jun
サイトメトリー20-1.indd
The role of NK cell receptor-expressing cell on anti-leukemia/cancer immunological effect Junji Tanaka, M.D., Ph.D. Hematology and Oncology, Hokkaido University Graduate School of Medicine Abstract NK
1 Department of Legal Medicine, Toyama University School of Medicine 2 3 4 5 6 7 8 Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama VEGF Key words
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
第124回日本医学会シンポジウム
III γ γ γ α γ Molecular Mechanism of Insulin Resistance by Adipocytes TAKASHI KADOWAKI Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo Key words γ 110 124 TNFα FFA 1,2
ÿþ
TNF ファミリー 腫瘍壊死因子 ( Tumor Necrosis Factor: TNF) は 固形がんに対して出血性の壊死を誘導する因子として発見されたサイトカインです TNF ファミリーには TNF-α リンフォトキシンα Fas リガンドや TRAIL などのアポトーシス誘導に関与するサイトカインのほか RANK リガンド OX40 リガンド APRIL など 20 種類近くに因子が同定されています
小児感染免疫第25巻第2号
2013 Vol. 25No. 2175 44 1972 28 1 Kikuchi s diseasekikuchifujmoto diseasehistiocytic necrotizing lymphadenitis Histiocytic necrotizing lymphadenitis, Kikuchi s disease, KikuchiFujimoto disease, subacute
myeloperoxidase MPO FCM CD.,CD.,CD., CD.,CD., HLA-DR., MPO. CD, CD, CD, CD, CD, CD, CD, CD, CD, CD b, CD, CDa, CD, TdT CD +CD +,XY,addition q/ French-
症例報告 岡智子 1,2), 室井一男 1,2), 森政樹 1,2), 松山智洋 1,2), 藤原慎一郎 1), 翁家国 1), 佐藤一也 1), 上田真寿 1), 鈴木隆浩 1), 尾崎勝俊 1), 永井正 1) 1,2), 小澤敬也 要 約 acute myeloblastic leukemia: AML minimal residual disease MRD AML AML CD +CD +CD
Sulfonylurea Receptors Pancreatic Type: SUR1 Cardiac Type: SUR2A Smooth Muscle Type: SUR2B Kir Channels uka-rp-1/kir6.1 BIR/Kir6.2 1) Ho K, et al : Cloning and expression of an inwardly rectifying ATP-regulated
15K00827 研究成果報告書
(TG) TG sterol regulatory element- binding protein (SREBP)-1c (Diabetes 53:560-569, 2004) SREBP-1c (1) SREBP-1c SREBP-1c liver X receptor (LXR)LXR O-Glc NAc (O-linked -N-acetyl glucosamine) (J Biol Chem
研究成果報告書
Functional analysis on EphB and ephrin-b expressing in gastric mucosaand their expression behavior in gastric ulcer and cancer EphBephrin-B EphBephrin-Bephrin-BEphB Gastric UnitEphB2 EphBephrin-BEphB/ephrin-B
スライド 1
1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
Fas and Ley antigen expression in polymorphonuclear leukocytes. Satoshi Nishizawa, Yukihiro Numabe and Kyuichi Kamoi Department of Periodontology, School of Dentistry at Tokyo, The Nippon Dental University
熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date Type URL Thesis or Di
熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date 2008-03-25 Type URL Thesis or Dissertation http://hdl.handle.net/2298/9448 Right 1
(Quality of Life; QL) QL (Nerve Growth Factor; NGF) NGF PC12 6- (6-HITC) NGF NGF NGF PTP1B 6-HITC PTP1B NGF PTP1B 6-HITC PTP1B 6-HITC NGF 6-HITC 6-HITC in vivo 464-8601 Tel: 052-789-4126 20-Hydroxyecdysone
Understanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
Untitled
上原記念生命科学財団研究報告集, 24(2010) 152. 随意的な骨形成誘導を可能にする前骨芽細胞増殖促進, アポトーシス抑制メカニズムの解析 森幹士 Key words:proliferation,anti-apoptosis,signal crosstalk,osteoblast,osteosarcoma 滋賀医科大学医学部整形外科学講座 緒言著者らは, 骨形成型腫瘍は, 骨環境に働きかけることで腫瘍増大と骨形成とに適する環境を作り出しているとの仮説を立て,
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
研究成果報告書(基金分)
The most remarkable characteristic of the mammalian neocortex is its layered structure. Because all, but only the mammalian species, have this layered structure in the telencephalon, it has been accepted
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
研究成果報告書(基金分)
(1) 種類 程度 肥満細胞数の測定と組織でのサ RT-PCR FACS () (1) NMU-/- IgE NMU IgE -/-NMU -/-B IgE NMU -/-B6 IgE NMU NMU CTLMC BMMC IgE NMU CTLMC 13 1. Hayakawa J, Mizukawa Y, Kurata M, Shiohara T: A syringotropic variant
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL http://hdl.handle.net/10130/526 Right Posted at the Institutional Resources for Unique Colle Available from
indd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
A Case of Biclonal Leukemia in a Child Yuichi OGURA,*1 Yasuhiko trox,*1 Takeshi ASANO,*1 Kouzou OHTA, *1 Kiyoshi KANEKO,*1 Yoshitaka FUKUNAGA, *1 Masa
A Case of Biclonal Leukemia in a Child Yuichi OGURA,*1 Yasuhiko trox,*1 Takeshi ASANO,*1 Kouzou OHTA, *1 Kiyoshi KANEKO,*1 Yoshitaka FUKUNAGA, *1 Masao YAMAMOTO,*1 Yutaka UEDA,*1 Kozue NAKAMURA*2 and Shuhki
MAP MAP MAP MAPKKK /MAP MAPKK /MAP MAPK MAPK MAP Microtubule associated protein 2 MAP Dundee Sturgill MAP MAP ERK1 ERK2 MAP Nerve Growth Factor NGF MA
四 細胞生物学 八月 東京大学理学部生物化学科卒業 すけ 昭和二八年 東京大学大学院理学系研究科博士課程修了 介 昭和五一年 理学博士 えい 日本学術振興会奨励研究員 栄 東京大学理学部助手 だ 六月 京都大学ウイルス研究所教授 田 五月 京都大学大学院理学研究科教授 にし 五年 京都大学大学院生命科学研究科教授 現在に至る 西 平成 九年 京都大学大学院生命科学研究科長 平成二一年まで 受賞者 専攻学科目
J Life Sci Res 2014; 12: Osaka Prefecture University Journal of Life Science Research Online ISSN
J Life Sci Res 2014; 12: 15-19 2014 Osaka Prefecture University Journal of Life Science Research Online ISSN 2186-5809 583-8555 3-7-30 577-8567 3-1-1 2014 9 11 2014 10 21 Exposure mild-level LED light
m «É w «Ÿ ÉÉ É É ÉÉ É É
É ÉÉÉÉ ÉÉ Zacc m «É w «Ÿ ÉÉ É É ÉÉ É É É É É É É É É ÉÉ É Uninephrectomy induces Progressive Glomerulosclerosis and Apoptosis in Anti Thy Glomerulonephritis VEGF Gene Expression is Correlated with Glomerular
untitled
19CRC/2009.8.8-9 T0 T1 T2 T3 T4 M0 N0 M1 19CRC 2009.8.8 1 2 N1 N2 N3 Stage 0 Stage I Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIC Stage IV Tis 3 4 5 6 1 19CRC/2009.8.8-9 7 8 Subtype of Breast Cancer
1315 (15)
(14) 1315 (15) 1316 (16) 1317 (17) 1318 (18) 1319 (19) 1320 (20) 1321 (21) 1322 quinidine, disopyramide, and procainamide in isolated atrial myocytes : Mediation by 2) Inoue H, et al: Effects of pentisomide
untitled
21 1 26 1 US6759035University of Southern California 1. A method for decreasing graft rejection of a solid organ by a recipient comprising: a) isolating peripheral blood mononuclear cells (PBMC) from a
untitled
RYZA IL & FAT CHEMICAL C., LTD. SAKURA EXTRACT Ver.1.4MK Ver. 1.4MK 1) 1300 1929 1 Ver. 1.4MK Sakura 1-caffeoyl---D-glucopyranoside quercetin 3---D-glucopyranoside 1) :, 4, 11-22 (1995). 2 Ver. 1.4MK 3
*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati
*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combination with angiotensin II induced hyperten sion chemotherapy
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity CHEMOTHERAPY MAR. 1989 Mble 1. Allcrgy in parients nduced by penams VOL. 37 NO. 3 Table 2. Allergy in patients induced by
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 ポスターについて 1. ポスター 貼 付 用 の 展 示 ボードは 縦 180 横 90cm の 大 きさです 2. 演 題 名 発 表 者 名 所 属 を 明 記 したもの(20 70cm) をご 用 意 ください 実 際 使 用 できるスペースは 155
ÿþ
インターロイキン インターロイキンは リンパ球や単球 マクロファージなどの免疫反応への寄与が知られる白血球から産生されることから 細胞間 ( inter-) 白血球 ( leukocyte -leukin) より Interleukin と名づけられました 現在までに 30 種類以上のインターロイキンが同定され 発見された順番に番号が付与されており 中にはケモカイン ( IL-8) やインターフェロン
日本組織適合性学会誌第23巻2号
Major Histocompatibility Complex 2016; 23 (2): 115 122 HLA 1 1) 1) HLA MHC 1900 HLA HLA キーワード : HLA HLA HLA HLA 2 HLA HLA HLA 3 1 1 HLA HLA 図 1 2016 6 30 2016 8 2 105 0013 1 10 14 3 5 TEL: 03 5776 0048
PowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
Key words: pure red cell anemia, allogeneic bone marrow transplantation.
Complete Recovery of Hemopoiesis Following Bone Marrow Transplantation in a Patient with Unresponsive Congenital Pure Red Cell Anemia Masami SHIMADA, Hideo MUGISHIMA, Mitsuhiko HARA, Masahiro MISAWA, Hideo
腫瘍細胞のMDM2 特異的阻害剤Nutlin-3aに対する感受性とp53変異
NAOSITE: Nagasaki University's Ac Title 腫瘍細胞の MDM2 特異的阻害剤 Nutlin-3a に対する感受性と p5 Author(s) 長谷川, 寛雄 ; 山田, 恭暉 ; 上平, 憲 Citation 臨床化学, 39(3), pp.246-252; 2010 Issue Date 2010-07 URL http://hdl.handle.net/10069/26653
Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 10 (2012) Key words ö γ µ Graves disease and Hashimoto s thyroiditis are autoimmune thyroid diseases. Graves disease causes
_統合化推進プログラム_金久チーム_サイトビジット資料
ライフサイエンスデータベース統合推進事業統合化推進プログラム ゲノム 疾患 医薬品のネットワークデータベース実施状況 京都大学化学研究所 金久 實 2018 年 8 月 22 日サイトビジット資料 KEGG NETWORK とは NAR DB Issue 2017 KEGG: new perspectives on genomes, pathways, diseases and drugs From
Treatment of Childhood Acute Lymphoblastic Leukemia with B-Cell Precursor Phenotype Arata WATANABE Department of Pediatrics, Nakadori General Hospital
Treatment of Childhood Acute Lymphoblastic Leukemia with B-Cell Precursor Phenotype Arata WATANABE Department of Pediatrics, Nakadori General Hospital Abstract Although more than 80% of children with acute
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells Abbreviation: LC=large cleaved nuclei, LNC=large non-cleaved nuclei, IMBL=immunoblastic nuclei,
1) Zapf J, Walter H and Froesch ER: Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.
ALDEFLUOR® 造血幹細胞／造血前駆細胞の新しい同定試薬
ALDEFLUOR Immunophenotyping ALDEFLUOR Primitive Mature or ALDH Aldehyde Dehydrogenase(ALDH) ALDH Stemness ALDH Primitive Mature ALDEFLUOR Intracellular enzymatic assay ALDEFLUOR BAAA ALDH BAA ALDH BAA
1) Roth, J., Glick, S. M., Yalow, R. S. and Berson, S. A.: Hypoglycemia: A potent stimulus to secretion of growth hormone. Science, 140, 987-988, 1963. 2) Ogawa, N.: Routine Ultramicro-Measurement of Human
研究成果報告書
X-SCID T NK Omenn T T 2007 2008 0menn T 1. 研究開始当初の背景 T T T T reversion T T 2. 研究の目的 RAG1/RAG2 Artemis T TCR T TCR 3. 研究の方法 RAG1/RAG2 μ μ μ μ μ μμ μμ μ 解析ダイアグラム 3-D display による TCR 多様性の評価 4. 研究成果 TCR T
Key words : influenza, nested-pcr, serotype
Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2
総括研究成果報告書
BILD 1 diethylstilbestrol (DES) estrogen DNA embryonic stem (ES) ES ES A3-1 ES ES Genetic Microsystems DNA 2 3 DNA DNA DNA BILD ES ES ES RNA RNA cdna DNA DNA estrogen MCF-7 RNA DNA ES mrna Differential
本文／ＹＡ１３００Ｂ
pp. T T B T T T NKT T Ig B BCR T TCR Generation of T-lineage cells and their functions Kazunori Onoé Division of Immunobiology, Department of Pathophysiology, Institute for Genetic Medicine, Hokkaido University,
PL Prof. Jean Gruenberg Department of Biochemistry, University of Geneva A L1 L A 18
PL L1L2 Y1Y5 S1S4 SS1SS8 LS PL Prof. Jean Gruenberg Department of Biochemistry, University of Geneva 8 30 15001600 A L1 L2 8 30 14001500 A 18 19 8 31 13001400 A Y1 Hirata A and Nakamura H. Localization
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
<91E F193FA967B95FA8ECB90FC89658BBF2D8FB4985E8F572E696E6464>
10 2 11 50 12 30 13 30 14 10 YAP YAP-01 YAP-02 YAP-03 YAP-04 YAP-05 YAP-06 YAP-07 YAP-08 YAP-09 YAP-10 1 2 34 Myc 1 2 1 2 3 1 2 3 4 5 DNA 1 23 DNA DNA 1 23 DNA 1 2 34 c-mpl 1 2 3 1 23 YAP-11 YAP-12 MR
untitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
} 無 アル ブミンラ ッ ト肝細 胞 への分離正常 肝細胞の移植 r一 昭和63年 度 科学 研究黄補 助金(一 般C>研 究成果報告書 ハ 平成元年3月 研究代表者 小川 勝洋 (旭 川医科 大学医学部教授)
} 無 アル ブミンラ ッ ト肝細 胞 への分離正常 肝細胞の移植 61570179 r一 昭和63年 度 科学 研究黄補 助金(一 般C>研 究成果報告書 ハ 平成元年3月 研究代表者 小川 勝洋 (旭 川医科 大学医学部教授) 1) Mito, M., Ebata, H., Kusano, M., Onishi, Y., Saito, T., Sakamoto, S. : Morphology
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
untitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
01.浅野.ppt
2010 14 23 1 15 2010 the 74 th Annual Scientific Meeting of American College of Rheumatology November 7 11, 2010 at Georgia World Congress Center, Atlanta, GA, USA 2284 SSc 142 Plenary Session: 3 Concurrent
免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
研究成果報告書(基金分)
RA RF ACPA RA RA RA RA RA IC IC RA RA IC RA IC RA IC RA RA RA IC 1 RA OA RA RA OA WinROOF RT-PCR ELISA RA RA RA OA 1 2 Thrombospondin-1 TSP-1 Platelet factor 4 PF-4RA RA RA RA 2 2 TSP-1 TSP-1 SS SLE RF
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
センシンレンのエタノール抽出液による白血病細胞株での抗腫瘍効果の検討
Evaluation of anti-tumor activity with the treatment of ethanol extract from Andrographis Paniculata in leukemic cell lines Hidehiko Akiyama 1), Kazuharu Suzuki 2), Toshiyuki Taniguchi 2) and Itsuro Katsuda
No21Vol1.indd
( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT)
cladribine 2-CdA ADA DCF HCL IFN- MTD LD50 LD90 DLT MDACC RWJPRI NHL ATL CLL 2-CdATP 5 -NT dckase (2-chloro-2 -deoxyadenosine) adenosine deaminase deoxycoformycin( ) hairy cell leukemia - (interferon alfa)
第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
Core Ethics Vol. DMD.... DMD.. PGD.... DMD
Core Ethics Vol. preimplantation genetic diagnosis PGD Franklin Franklin = : DMD a b Core Ethics Vol. DMD.... DMD.. PGD.... DMD PCR polymerase chain reaction FISH fluorescence in situ hybridization PCR
11713_SciSig_vol14ｐ
Science Signaling 日 本 語 版 ダイジェスト vol.14 http://www.sciencesignaling.org/ ScienceSignaling.org Science Signaling Science Signaling Science Signaling Editorial Guide Focus Issue:TOR シグナル 伝 達 2 つの Focus Issue:
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
Title 骨量規定転写因子シュニュリ3の新規標的遺伝子同定と機能解析 Author(s) 石堂, 康弘 Citation Issue Date 2014-06-27 URL http://hdl.handle.net/10232/24125 http://ir.kagoshima-u.ac.jp adult (Schnurri, Shn)3/Hivep3 Runx2 Shn/Hivep Shn3
1 CHL 診断的価値の高い RS 細胞は 大型の明瞭な核小体 を有し 核小体周囲に明庭 halo を伴う巨細胞で 対称性 2 核 鏡面像 mirror image や多核を示す 図 1 RS 細胞の類縁細胞としては単一核の Hodgkin 細 胞 結節硬化型に認められる lacunar cell
1 Key Words Hodgkin lymphoma histopathology) WHO WHO classification 170 1832 Thomas Hodgkin PCR B monoclonal 1,2 2001 WHO 3 1 1947 Jackson Parker 1966 Rye 1990 Rye 1994 REAL 2001 WHO 100,000 3.5 5 1/3